VRTX Vertex Pharmaceuticals

Q2 2025 10-Q

Filed: Aug 5, 2025Period ending Jun 30, 2025

Health Care

Pharmaceutical PreparationsSEC EDGAR

Vertex Pharmaceuticals (VRTX) 10-Q quarterly report for Q2 2025, filed with SEC EDGAR on Aug 5, 2025 for the fiscal period ending Jun 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q2 2025 10-Q

Risk Factors

• No new or materially changed risk factors disclosed in quarterly filing versus most recent 10-K
• Regulatory risk: ongoing FDA interactions and accelerated approvals remain critical for clinical trial timelines and product launches

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$3.0B

Net Income

$1.0B

Net Margin

34.8%

Source: XBRL data from Vertex Pharmaceuticals Q2 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Vertex Pharmaceuticals Quarterly Reports

Q3 2025 10-Q

Q1 2025 10-Q

Get deeper insights on Vertex Pharmaceuticals

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.